Eikon Therapeutics, Inc. (EIKN) stock
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.17+0.02 (+0.39%)
Close on Nov 18, 2026Market cap $280.03MP/E –Yield –
Eikon Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$93.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$87.34M | – |
| Q2 FY2025 | Jun 30, 2025 | -$109.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$71.38M | – |
See a number that looks wrong?